FindTrial
Sign In

Blood test for endothelin as marker for severe COVID 19 related disease

To evaluate role of endothelin 1 as marker for severe COVID 19 related disease : An observational cohort pilot study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/07/034933
Enrollment
40
Registered
2021-07-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: B998- Other infectious disease

Interventions

None listed

Sponsors

All india Institute of Medical Science Rishikesh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: COVID 19 cases confirmed by RTPCR Age greater than 18 years of age Informed consent

Exclusion criteria

Exclusion criteria: Infection other than COVID Lung malignancy Chronic obstructive Pulmonary disease Chronic renal failure Malignancy Connective tissue disorders Age greater than 90 years Advanced liver disease

Design outcomes

Primary

MeasureTime frame
Correlation of serum endothelin level with severity of Lung diseaseTimepoint: Correlation of serum endothelin level with severity of Lung disease—

Secondary

MeasureTime frame
Correlation of serum endothelin levels to severe COVID diseaseTimepoint: 14 days since symptom onset—

Countries

India

Contacts

Public ContactRohit Walia

All India Institute of Medical Science Rishikesh

rwalia7731@yahoo.in8800492549

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026